Hunan Hansen Pharmaceutical Co. Ltd. (002412.SZ) Latest Company News

Sep 14, 2026, 09:08 UTC
Hansen Pharmaceutical plans to inject 20 million yuan of its own funds into its wholly owned subsidiary Hansen Health Industry (Hunan) Co., Ltd., raising the subsidiary's registered capital from 240 million yuan to 260 million yuan while retaining 100% ownership.
Source:
- finance.sina.cn
Aug 27, 2026, 08:47 UTC
Hansen Pharmaceutical completed the change registration of its Drug Manufacturing License, obtaining a new license from the Hunan Provincial Drug Administration, valid until November 6, 2030.
Source:
- finance.sina.cn
Aug 25, 2026, 05:56 UTC
On August 25, 2026, the Shenwan primary industry pharmaceutical and biological sector rose 1.22% to 7852.96 points at midday, with multiple stocks hitting the daily limit, including Transgen Life, Jiheng Pharmaceutical, Weiguang Biological, Huasen Pharmaceutical, Hansen Pharmaceutical, and Hainan Haiyao.
Source:
- m.21jingji.com
Aug 24, 2026, 09:01 UTC
Hansen Pharmaceutical released its 2026 semi-annual report, reporting revenue of 476 million yuan, down 6.42% year-on-year, and net profit attributable to shareholders of 107 million yuan, up 55.52% year-on-year.
Source:
- finance.sina.cn
Jul 28, 2026, 10:54 UTC
Hansen Pharmaceutical plans to terminate its 173-mu development land investment project for expanding basic drug production lines, originally initiated in 2011 and re-contracted in 2022, due to industry changes and land listing issues, with no material adverse impact on operations.
Source:
- finance.sina.cn

002412.SZ

Hansen Pharmaceutical plans to inject 20 million yuan of its own funds into its wholly owned subsidiary Hansen Health Industry (Hunan) Co., Ltd., raising the subsidiary's registered capital from 240 million yuan to 260 million yuan while retaining 100% ownership.

Hansen Pharmaceutical completed the change registration of its Drug Manufacturing License, obtaining a new license from the Hunan Provincial Drug Administration, valid until November 6, 2030.

Hansen Pharmaceutical released its 2026 semi-annual report, reporting revenue of 476 million yuan, down 6.42% year-on-year, and net profit attributable to shareholders of 107 million yuan, up 55.52% year-on-year.

Hansen Pharmaceutical plans to terminate its 173-mu development land investment project for expanding basic drug production lines, originally initiated in 2011 and re-contracted in 2022, due to industry changes and land listing issues, with no material adverse impact on operations.